The 10-second takeaway
For the quarter ended March 31 (Q1), Boston Scientific met expectations on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted and GAAP earnings per share improved significantly.
Gross margin and operating margin contracted, while net margin improved.
Boston Scientific reported revenue of $1.87 billion. The 21 analysts polled by S&P Capital IQ looked for revenue of $1.86 billion on the same basis. GAAP reported sales were 3.1% lower than the prior-year quarter's $1.93 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.09. The 24 earnings estimates compiled by S&P Capital IQ forecast $0.08 per share on the same basis. GAAP EPS of $0.08 for Q1 were 167% higher than the prior-year quarter's $0.03 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 63.6%, 150 basis points worse than the prior-year quarter. Operating margin was 11.6%, 480 basis points worse than the prior-year quarter. Net margin was 6.1%, 370 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.9 billion. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $7.48 billion. The average EPS estimate is $0.42.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 750 members rating the stock outperform and 186 members rating it underperform. Among 182 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 165 give Boston Scientific a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.64.
The health-care investing landscape is littered with also-rans and a few major winners. Is Boston Scientific performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Boston Scientific to My Watchlist.